THE SETPOINT STUDY: DOES EARLY THERAPY ALTER THE VIROLOGIC SETPOINT?

设定点研究：早期治疗会改变病毒学设定点吗？

• 批准号: 7607422
• 负责人: PAUL SAX
• 金额: $ 0.54万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607422
• 关键词: Anti-HIV Agents; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; HIV Infections; Institution; Learning; Lopinavir/Ritonavir; Purpose; Research; Research Personnel; Resources; Source; Tenofovir; United States National Institutes of Health; emtricitabine; Anti-HIV Agents; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; HIV Infections; Institution; Learning; Lopinavir/Ritonavir; Purpose; Research; Research Personnel; Resources; Source; Tenofovir; United States National Institutes of Health; emtricitabine

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of the study is to learn if treating people during early HIV infection is beneficial. This study will evaluate how safe and effective a combination of anti-HIV drugs (emtricitabine/Tenofovir DF and Lopinavir/Ritonavir) is for people with recently acquired HIV infection.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 该研究的目的是学习在早期艾滋病毒感染期间治疗人是否有益。 这项研究将评估抗HIV药物（Emtricerabine/Tenofovir DF和Lopinavir/Ritonavir）的安全和有效组合，用于最近获得HIV感染的患者。